Delivery Order SPE2DB25D3110-SPE2DB25FTEHU
- Not listed
- The Defense Logistics Agency awarded a $1,041.42 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of July 30, 2025. This is a firm fixed price, non-set-aside contract with performance at AmerisourceBergen's Conshohocken, Pennsylvania facility. The delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion prime vendor agreement running...
- The Defense Logistics Agency awarded a $19,727.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 4, 2025. This non-competitive delivery order, issued on September 3, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $1 billion through December 2026. The pharmaceutical product will be delivered...
- The Defense Logistics Agency awarded a $9,735.80 delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract is firm fixed price with no set-aside designation and is scheduled for completion by August 25, 2025. AmerisourceBergen will perform work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a delivery order valued at $10,440.68 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract, awarded on September 2, 2025, with an ultimate completion date of September 3, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the...
- The Defense Logistics Agency awarded a $9,811.24 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors on September 9, 2025, with completion targeted for September 10, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen, headquartered in...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,011.08 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of August 21, 2025. This firm fixed-price delivery order, awarded on August 20, 2025, represents a non-set-aside competitive procurement with performance directed to AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $20,056.39 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injector pens. The contract, which was not set-aside and competitively awarded, is scheduled for completion by August 18, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $40,273.98 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors. This firm fixed price, non-set-aside contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025. The pharmaceutical products will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office. Repatha is a PCSK9 inhibitor used to treat high...
- The Defense Logistics Agency awarded a $44,398.54 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors. This competitive, firm fixed-price contract was executed on August 20, 2025, with an ultimate completion date of August 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $9,833.30 firm fixed-price delivery order for Repatha 140 mg/mL SureClick auto-injectors on August 25, 2025. This non-set-aside, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order is scheduled for completion by August...
- SPE2DB25D3110Indefinite Delivery Contract
- SPE2DB25D3110-SPE2DB25FTEHUDelivery Order
The Defense Logistics Agency awarded a $4,911.24 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The award was issued on September 9, 2025, and performance will be executed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.999 billion prime contract vehicle designated SPE2DX and running through December 2026 that enables the company to supply pharmaceutical products and medical supplies globally to support military healthcare programs. Repatha is a PCSK9 inhibitor used to treat high cholesterol and reduce cardiovascular risk in patients with familial hypercholesterolemia or established cardiovascular disease. AmerisourceBergen's extensive federal contract portfolio demonstrates its critical role as a primary pharmaceutical distributor for the Defense Health Agency and military medical systems. The company's demonstrated capability to compete successfully across multiple therapeutic domains and deliver medical commodities of varying values positions it as a key vendor supporting federal healthcare requirements, particularly within the military and veteran healthcare infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 9/9/25 |